CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Purchase | +300,000 | $10.00 | $3.0M | 2,310,924 |
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion · Series A Preferred Stock | −890,476 | 0 | ||
| 2016-04-12 | Novartis Bioventures Ltd 10% owner | Conversion · Series B Preferred Stock | −1,120,448 | 0 | ||
| 2016-04-12 | Lowe David George CEO and President | Conversion | +5,658 | 5,658 | ||
| 2016-04-12 | Lowe David George CEO and President | Conversion · Series A Preferred Stock | −2,857 | 0 | ||
| 2016-04-12 | Lowe David George CEO and President | Conversion · Series B Preferred Stock | −2,801 | 0 | ||
| 2016-04-12 | Cox Russell J. Director | Purchase | +7,000 | $10.00 | $70K | 7,000 |
Page 21 of 21 · 407 trades